Everolimus for the second-line treatment of advanced and/or metastatic renal cell cancer: a critique of the submission from Novartis

Pitt M, Crathorne L, Moxham T, Bond M, Hyde C. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (review of Technology Appraisal No.111): a systematic review and economic model. Health Technology Assessment 2010;14(2): 41-46.